Taiwan
· Delayed Price · Currency is TWD Diamond Biofund Statistics
Total Valuation
Diamond Biofund has a market cap or net worth of TWD 26.45 billion. The enterprise value is 20.57 billion.
| Market Cap | 26.45B |
| Enterprise Value | 20.57B |
Important Dates
The last earnings date was Monday, November 11, 2024.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Diamond Biofund has 850.47 million shares outstanding. The number of shares has increased by 12.81% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 850.47M |
| Shares Change (YoY) | +12.81% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 25.28% |
| Owned by Institutions (%) | 5.18% |
| Float | 178.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.38 |
| P/TBV Ratio | 2.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -13.18 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.60 |
Financial Position
The company has a current ratio of 69.93, with a Debt / Equity ratio of 0.01.
| Current Ratio | 69.93 |
| Quick Ratio | 69.91 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.03 |
| Interest Coverage | -432.10 |
Financial Efficiency
Return on equity (ROE) is -13.12% and return on invested capital (ROIC) is -8.25%.
| Return on Equity (ROE) | -13.12% |
| Return on Assets (ROA) | -8.21% |
| Return on Capital (ROIC) | -8.25% |
| Revenue Per Employee | -50.24M |
| Profits Per Employee | -55.75M |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.91% in the last 52 weeks. The beta is 1.52, so Diamond Biofund's price volatility has been higher than the market average.
| Beta (5Y) | 1.52 |
| 52-Week Price Change | -26.91% |
| 50-Day Moving Average | 33.47 |
| 200-Day Moving Average | 38.56 |
| Relative Strength Index (RSI) | 42.51 |
| Average Volume (20 Days) | 424,709 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Diamond Biofund had revenue of TWD -1.41 billion and -1.56 billion in losses. Loss per share was -1.84.
| Revenue | -1.41B |
| Gross Profit | -1.41B |
| Operating Income | -1.58B |
| Pretax Income | -1.56B |
| Net Income | -1.56B |
| EBITDA | -1.57B |
| EBIT | -1.58B |
| Loss Per Share | -1.84 |
Balance Sheet
The company has 6.00 billion in cash and 123.70 million in debt, giving a net cash position of 5.88 billion or 6.91 per share.
| Cash & Cash Equivalents | 6.00B |
| Total Debt | 123.70M |
| Net Cash | 5.88B |
| Net Cash Per Share | 6.91 |
| Equity (Book Value) | 11.13B |
| Book Value Per Share | 13.08 |
| Working Capital | 5.92B |
Cash Flow
In the last 12 months, operating cash flow was -4.44 billion and capital expenditures -32.88 million, giving a free cash flow of -4.47 billion.
| Operating Cash Flow | -4.44B |
| Capital Expenditures | -32.88M |
| Free Cash Flow | -4.47B |
| FCF Per Share | -5.26 |
Margins
| Gross Margin | n/a |
| Operating Margin | 112.15% |
| Pretax Margin | 110.97% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Diamond Biofund does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.81% |
| Shareholder Yield | -12.81% |
| Earnings Yield | -5.92% |
| FCF Yield | -16.91% |
Stock Splits
The last stock split was on August 7, 2023. It was a forward split with a ratio of 1.18.
| Last Split Date | Aug 7, 2023 |
| Split Type | Forward |
| Split Ratio | 1.18 |
Scores
Diamond Biofund has an Altman Z-Score of 116.88.
| Altman Z-Score | 116.88 |
| Piotroski F-Score | n/a |